Compare PRLB & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRLB | MLTX |
|---|---|---|
| Founded | 1999 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 979.8M |
| IPO Year | 2012 | N/A |
| Metric | PRLB | MLTX |
|---|---|---|
| Price | $53.65 | $15.87 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $53.00 | $22.22 |
| AVG Volume (30 Days) | 124.7K | ★ 3.5M |
| Earning Date | 02-06-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $518,384,000.00 | N/A |
| Revenue This Year | $7.07 | N/A |
| Revenue Next Year | $4.87 | N/A |
| P/E Ratio | $90.17 | ★ N/A |
| Revenue Growth | ★ 2.82 | N/A |
| 52 Week Low | $29.59 | $5.95 |
| 52 Week High | $56.60 | $62.75 |
| Indicator | PRLB | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.19 | 54.01 |
| Support Level | $52.95 | $15.70 |
| Resistance Level | $56.60 | $16.86 |
| Average True Range (ATR) | 1.64 | 1.29 |
| MACD | -0.03 | 0.09 |
| Stochastic Oscillator | 51.68 | 62.14 |
Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. Proto Labs uses injection molding, computer numerical control machining, and 3-D printing to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. Geographically, a majority of the company's revenue is derived from the United States and the rest from Europe.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.